Full history for every metric is available with a Kvantra account
Guangdong Taiantang Pharmaceutical Co., Ltd. (002433.SZ)
Key financial summary
Financials in CNY| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY m | 3,315 | 4,013 | 3,582 | 2,264 | 725 | 410 | 338 |
| Operating profit | CNY m | -2,214 | -2,163 | |||||
| Net profit | CNY m | 271 | 96 | 22 | -832 | -854 | -2,210 | -2,203 |
| EPS reported | CNY | -2.88 | -2.88 | |||||
| Operating cashflow per share | CNY | -0.13 | -0.13 | |||||
| Capex per share | CNY | 0.04 | 0.04 | |||||
| FCF per share | CNY | -0.17 | -0.17 | |||||
| Free cash flow | CNY m | -129 | -51 | |||||
| Net debt | CNY m | 1,129 | 1,081 | |||||
| Book value equity | CNY m | 434 | 381 | |||||
| Book value per share | CNY | 0.52 | 0.50 | |||||
| Number of shares | m | 767.39 | 766.77 | |||||
| DPS (TTM paid) | CNY | 0.10 | 0.00 |
Financial summary
Financials in CNY| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 4.40 | 0.54 | |||||
| P/S LTM | x | 4.66 | 0.61 | |||||
| P/FCF LTM | x | -14.84 | -4.05 | |||||
| EV/EBITDA LTM | x | -9.71 | -3.68 | |||||
| EV/Sales LTM | x | 7.41 | 3.81 | |||||
| Earnings Yield LTM | % | -115.66% | -1066.7% | |||||
| FCF Yield | % | -6.74% | -24.71% | |||||
| Quality | ||||||||
| ROE | % | -509.21% | -109.18% | |||||
| ROIC | % | -101.42% | -101.42% | |||||
| Operating margin | % | -539.49% | -539.49% | |||||
| Gross margin | % | 16.85% | 16.85% | |||||
| FCF/Sales | % | -31.38% | -31.38% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -43.39% | -49.76% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 3.83% | 0.00% | |||||
| Dividend Growth | % | - | - | |||||
| Payout Ratio | % | -3.31% | -2.36% | |||||
| FCF/Debt | x | -0.10 | -0.04 | |||||
| Net Debt/EBITDA | x | -3.61 | -3.61 | |||||
| EBIT/Net interest | x | -11.30 | -11.30 | |||||
| Net debt/market cap | % | 59.08% | 522.21% | |||||
| Net debt/Equity | x | 2.60 | 2.84 | |||||
| Gross debt/equity | x | 2.88 | 3.28 | |||||
Company overview
Guangdong Taiantang Pharmaceutical Co., Ltd. operates within China, specializing in the entire lifecycle of traditional Chinese patent medicines, from initial research and development to manufacturing and distribution. Their diverse product portfolio encompasses various dosage forms, including topical creams and ointments, oral tablets, capsules, pills, and liquid solutions. These pharmaceutical products cater to a wide array of therapeutic areas, such as reproductive and dermatological health, cardiovascular and cerebrovascular conditions, and anti-inflammatory treatments, among others. Additionally, the company is actively involved in the acquisition, cultivation, processing, and sale of raw Chinese medicinal materials. Founded in 1995, its corporate headquarters are situated in Shantou, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Guangdong Taiantang Pharmaceutical Co., Ltd. (002433.SZ)
Guangdong Taiantang Pharmaceutical Co., Ltd. operates within China, specializing in the entire lifecycle of traditional Chinese patent medicines, from initial research and development to manufacturing and distribution. Their diverse product portfolio encompasses various dosage forms, including topical creams and ointments, oral tablets, capsules, pills, and liquid solutions. These pharmaceutical products cater to a wide array of therapeutic areas, such as reproductive and dermatological health, cardiovascular and cerebrovascular conditions, and anti-inflammatory treatments, among others. Additionally, the company is actively involved in the acquisition, cultivation, processing, and sale of raw Chinese medicinal materials. Founded in 1995, its corporate headquarters are situated in Shantou, China.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free